Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

Novartis gains label boost for Cosentyx

Updated label allows dosing flexibility of up to 300mg

Celgene building

Celgene to launch five new products through to 2020

Two of which are CAR-T candidates

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

- PMLiVE

Alexion targets RNAi with $637m Dicerna deal

Bolsters pipeline ahead of Soliris patent protection loss

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

Bayer symbol

Bayer preps filings for new prostate cancer drug

If approved, will challenge Xtandi and Erleada

- PMLiVE

FCB’s new offering, Huntsworth Health buys Navience and Cuttsy+Cuttsy launch e-book

The latest healthcare advertising, digital, PR and creative news

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links